Portal Login:
  • Clients
  • Providers
  • Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar
  • Skip to footer
    Portal Login:
  • Clients
  • Providers
  • About MCN
  • Careers
  • MCNTalk
  • Contact Us

MCN | Medical Consultants Network

The Power of a Second Look

  • Services
    • Independent Medical Examinations
    • Medical Peer Reviews
    • Bill Review Services
    • Utilization Reviews
  • Expertise
    • Short and Long-Term Disability
    • Workers’ Compensation
    • Auto/PIP/Casualty/Liability
    • Independent Review Organization Services
  • For Clients
  • For Providers
  • Your Exam
    • About Your Exam
    • About Your External Review
    • Contact & Scheduling
  • Schedule Now
  • About MCN
  • MCNTalk
  • Careers
  • Contact Us

MCNTalk
News, Insights & Opinions

Home / MCNTalk / New Gene Tests and the Potential Effect on Long-Term Care In...

May 25, 2017

New Gene Tests and the Potential Effect on Long-Term Care Insurance

Last month the Food and Drug Administration gave its approval for the gene testing company 23andMe to offer tests assessing risks for developing conditions such as Parkinson’s and celiac disease. Other genetics companies are planning to follow suit shortly and offer tests that will give people a better idea of what their “medical futures” look like. Although this may seem like an excellent step forward, these tests could actually prove to be a disaster for companies selling long-term care insurance.  The issue does not currently lie with employment or health insurance because the Genetic Information Nondiscrimination Act protects employees from being asked to take gene tests and results cannot be used in employment decisions. However, unlike medical insurers, companies selling long-term care insurance can ask about health status and are permitted to consider future health when making decisions on whom they will insure and how much they will charge. The issue for these companies is that they believe many customers will choose not to reveal this information and genetics companies promise not to disclose anything to third parties.

Increasing numbers of people at low risk might decide the insurance was not worth the rising price. Even many at high risk would eventually find the policies unaffordable. It is the definition of an insurance death spiral. – New York Times

Read more from the New York Times here.

Share this:

  • Twitter
  • Email
  • More
  • Facebook
  • Reddit
  • Print

Leave a Comment

Previous Post
Next Post

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Recent Posts

  • The Quality Divide: What Makes a Quality IME Physician?
  • The Quality Divide: Is Your Vendor Driving IME Excellence?
  • The Quality Divide: When and How to Request an IME?
  • April Clinic Calendars Are Available
  • MCN’s Client Portal Login Page is Changing

Archives

Footer


  • Twitter
  • LinkedIn

Quick Links

  • Services
  • Expertise
  • About MCN
  • Careers

Division Headquarters

MCN
1200 5th Ave., Ste. 650
Seattle, WA 98101

See all offices

Email Us

General Inquiries: info@mcn.com
Sales & Marketing: marketing@mcn.com

Call Us

206.343.6100
800.248.6269

© Copyright 2023 Mitchell International, Inc. All Rights Reserved.

  • Privacy Policy
  • Sitemap